Table 3 Median PDDs of the most used antibiotic molecules provided for therapeutic purposes by age classes.
From: Use of multiple metrics to assess antibiotic use in Italian children’s hospitals
Antibiotic molecules | Median PDDs (g) by age classes | ||||||
|---|---|---|---|---|---|---|---|
No. of therapies | DDD (g) | 0–11 Months (IQR) | 12–23 Months (IQR) | 2–4 Years (IQR) | 5–9 Years (IQR) | ≥ 10 Years (IQR) | |
Piperacillin and beta-lactamase inhibitors | 78 | 14.0 | 0.3 (0.07–0.6) | 1.0 (0.8–1.6) | 3.0 (2.7–4.5) | 7.0 (6.0–9.0) | 12.0 (9.0–12.0) |
Meropenem | 71 | 2.0 | 0.1 (0.06–0.1) | 0.3 (0.2–0.4) | 0.8 (0.6–1.3) | 1.8 (1.1–1.9) | 3.0 (2.1–4.5) |
Amoxicillin and beta-lactamase inhibitors | 72 | 3.0 | 0.3 (0.3–0.3) | 0.7 (0.4–0.8) | 0.7 (0.4–1.2) | 1.5 (1.0–1.8) | 2.0 (1.7–2.0) |
Sulfamethoxazole and trimethoprim | 70 | 1.9 | 0.01 (0.01–0.01) | 0.3 (0.04–0.4) | 0.1 (0.05–0.3) | 0.2 (0.09–0.5) | 0.3 (0.2–0.3) |
Amikacin | 64 | 1.0 | 0.02 (0.02–0.03) | 0.06 (0.05–0.07) | 0.2 (0.2–0.6) | 0.4 (0.3–0.4) | 0.7 (0.5–1.0) |
Ceftriaxone | 63 | 2.0 | 0.3 (0.3–0.3) | 0.4 (0.4–0.7) | 1.0 (0.5–1.0) | 1.5 (1.0–2.0) | 2.0 (1.0–2.0) |
Cefazolin | 61 | 3.0 | 0.1 (0.05–0.2) | 0.3 (0.2–0.3) | 0.7 (0.5–1.0) | 1.3 (0.6–1.8) | 2.0 (2.0–3.0) |
Gentamicin | 55 | 0.2 | 0.01 (0.004–0.01) | 0.01 (0.01–0.02) | 0.05 (0.04–0.06) | 0.1 (0.08–0.1) | 0.2 (0.1–0.3) |
